세계의 디지털 치료제(DTx) 시장 : 공급별, 수익 모델별, 용도별 - 예측(-2028년)
Digital Therapeutics (DTx) Market by Offerings (Platform, Virtual Reality/Games), Revenue Model (Subscription, Value Based), Application (Therapy (Diabetes, Obesity, CNS, Respiratory, CVD), Drug Adherence, Rehab/Patient care) - Global Forecast to 2028
상품코드:1419281
리서치사:MarketsandMarkets
발행일:2024년 01월
페이지 정보:영문 297 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
보고서 개요
조사 범위
조사 대상 연도
2021-2028년
기준 연도
2022년
예측 기간
2023-2028년
단위
금액(달러)
부문
제공, 수익 모델, 판매 채널, 용도, 지역별
대상 지역
북미, 유럽, 아시아태평양, 중남미, 중동 및 아프리카
디지털 치료제(DTx) 시장 규모는 예측 기간 동안 29.1%의 CAGR을 기록하며 2023년 61억 달러에서 2028년 219억 달러에 달할 것으로 예상됩니다.
DTx의 급속한 보급은 만성질환을 앓고 있는 환자 수 증가와 투자 확대 등의 요인에 힘입어 빠르게 확산되고 있습니다. 반면, 신흥국 시장에서 DTx 프로그램에 대한 인지도와 접근성 부족, 기존 의료 서비스 제공자의 저항, 불균등한 지불 모델 등이 시장 성장을 저해하는 요인으로 작용하고 있습니다.
수익 모델별로는 구독 기반 부문이 예측 기간 동안 가장 큰 규모와 가장 빠른 성장을 보일 것으로 예상되며, DTx는 장기적인 건강 결과를 목표로 하는 경우가 많기 때문에 사용자는 장기적으로 프로그램에 참여해야 합니다. 구독 모델은 인센티브와 플랫폼 기능에 대한 지속적인 액세스를 제공함으로써 사용자의 헌신을 유도합니다.
용도별로는 당뇨병 치료 부문이 2022년 가장 큰 점유율을 차지하며 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다. 당뇨병 유병률 증가, 당뇨병과 관련된 막대한 의료 비용, 비용 효율적인 솔루션을 통한 부담 경감에 초점을 맞춘 정부 이니셔티브의 증가 등이 성장 동력으로 작용할 것으로 보입니다.
지역별로는 북미 지역이 2022년 큰 비중을 차지했습니다. 기술 개발 자금을 지원하는 정부 제도와 DTx에 대한 유리한 상환 구조와 같은 요인이 이 지역의 시장 성장을 촉진할 것으로 예상됩니다. 또한, 이 지역의 보험사, 의료 제공자 및 기타 이해관계자들은 DTx의 임상적 효과와 비용 효율성을 인식하고 적극적으로 도입하고 있습니다. 이러한 초기 채택은 다양한 의료 환경에서 광범위한 채택을 촉진하고 있습니다.
세계의 디지털 치료제(DTx) 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 기술 및 특허 동향, 규제 및 리베이트 환경, 사례 분석, 시장 규모 추이 및 예측, 각 부문별·지역별 상세 분석, 경쟁 구도, 주요 기업 개요 등을 정리하고 있습니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 주요 인사이트
제5장 시장 개요
시장 역학
성장 촉진요인
성장 억제요인
기회
과제
업계 동향
기술 분석
밸류체인 분석
생태계 분석
파이프라인 제품
사례 연구 분석
Porter's Five Forces 분석
규제 상황
가격 분석
상환 시나리오
특허 분석
주요 회의와 이벤트
주요 이해관계자와 구입 기준
매출 변화와 DTx 시장의 새로운 수익원
투자 상황
제6장 디지털 치료제(DTx) 시장 : 서비스별
소프트웨어/플랫폼
프로그램
가상현실/게임
제7장 디지털 치료제(DTx) 시장 : 용도별
치료/케어 관련
당뇨병
중추신경계(CNS) 장애
금연
만성 호흡기질환
근골격계 질환
심혈관질환
복약 준수
위장장애
재활·환자 케어
약물 사용 장애·중독 관리
기타
예방 용도
당뇨병 전증
비만
영양
라이프스타일 관리
기타
제8장 디지털 치료제(DTx) 시장 : 수익 모델별
구독 기반 모델
원타임 구입/연간 라이선싱 모델
성과/가치 기반 모델
제9장 디지털 치료제(DTx) 시장 : 판매 채널별
B2B 판매 채널
보험자
고용주
제약회사
프로바이더
기타
B2C 판매 채널
의료진
환자
제10장 디지털 치료제(DTx) 시장 : 지역별
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
제11장 경쟁 상황
개요
주요 기업의 전략
주요 기업 매출 점유율 분석
시장 점유율 분석
기업 평가 매트릭스
스타트업/중소기업의 기업 평가 매트릭스
경쟁 시나리오와 동향
제12장 기업 개요
주요 기업
NOOM, INC.
TELADOC HEALTH, INC.
OMADA HEALTH, INC.
WELLDOC, INC.
COGNIFIT, INC.
HEADSPACE HEALTH
PROPELLER HEALTH
2MORROW, INC.
CANARY HEALTH
CLICK THERAPEUTICS, INC.
AKILI, INC.
WELLTHY THERAPEUTICS PVT. LTD.
COGNOA, INC.
TWILL INC.
KAIA HEALTH SOFTWARE GMBH
BETTER THERAPEUTICS, INC.
REALIZEDCARE
BIOFOURMIS
AYOGO INCORPORATED
AMALGAM RX, INC.
기타 기업
MINDABLE HEALTH GMBH
VIRTA HEALTH CORP.
HINGE HEALTH
OREXO AB
FREESPIRA, INC.
제13장 부록
ksm
영문 목차
영문목차
Report Description
Scope of the Report
Years Considered for the Study
2021-2028
Base Year
2022
Forecast Period
2023-2028
Units Considered
Value (USD) Billion
Segments
By Offering, By Revenue Model, Sales Channel, Application, and Region
Regions covered
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
The digital therapeutics market is projected to reach USD 21.9 billion by 2028 from USD 6.1 billion in 2023, at a CAGR of 29.1% during the forecast period. The rapid adoption of digital therapeutics is driven by factors such as the increasing number of patients grappling with chronic diseases and escalating investments in this sector. Nonetheless, impediments to market growth include a lack of awareness and access to digital therapeutics programs in developing nations, resistance from traditional healthcare providers, and the existence of uneven payment models.
"The subscription-based revenue model segment represents the largest and fastest-growing category in the market over the forecast period."
The revenue model segment the digital therapeutics market is categorized into subscription, one-time purchase/licensing, and outcome/value based. In 2022, the subscription segment held the largest market share. Digital therapeutics often aim for long-term health outcomes, requiring users to commit to the program over an extended period. Subscription models encourage user commitment by offering incentives and continuous access to the platform's features.
"Diabetes segment is expected to grow at the highest rate during the forecast period."
Concerning the type of treatment/care-related application, the digital therapeutics market is categorized into diabetes, CNS disorders, chronic respiratory diseases, musculoskeletal disorders, cardiovascular diseases, smoking cessation, medication adherence, gastrointestinal disorders, substance use disorders & addiction management, rehabilitation & patient care, and other treatment/care-related applications.
Within the category of treatment/care-related applications, the diabetes segment is poised to register the highest growth rate during the forecast period. The market for digital therapeutics in diabetes accounted for the largest share in 2022. The driving factors include the increasing prevalence of diabetes, the significant healthcare costs associated with the condition, and rising government initiatives focused on alleviating the burden through cost-effective solutions.
"The B2B segment is expected to grow with the highest CAGR during the forecast period."
With respect to the sales channel, the digital therapeutics market is segmented into business-to-customer (B2C) and business-to-business (B2B). The B2B segment is anticipated to exhibit the highest CAGR during the forecast period, attributed to the growing partnerships of pharmaceutical companies with digital health companies to integrate digital therapeutics with their drug products. Pharmaceutical companies are actively engaging in strategic partnerships and acquisitions with digital therapeutics providers. These collaborations allow pharmaceutical companies to integrate digital therapeutics into their broader healthcare solutions, offering a holistic approach to patient care. Additionally, payers, including insurance companies and healthcare providers, are increasingly embracing value-based care models. Digital therapeutics align with these models by emphasizing outcomes, prevention, and cost-effectiveness. Payers see the potential of DTx in reducing healthcare costs through preventive interventions, ultimately driving adoption.
"North America to be the largest and the fastest-growing regional market."
North America, comprising of the US and Canada, held the lion's share for digital therapeutics market in 2022. Factors such as the government schemes to fund technological advancements progresses combined with the favorable reimbursement structure for digital therapeutics are projected to the drive market growth in this region. Additionally, payers and healthcare providers in North America have been early adopters of digital therapeutics. The region has witnessed a proactive approach from insurance companies, healthcare providers, and other stakeholders in recognizing the clinical and cost-effectiveness of DTx. This early buy-in has driven widespread adoption across different healthcare settings.
The primary interviews conducted for this report can be categorized as follows:
By Company Type: Tier 1 (50%), Tier 2 (30%), and Tier 3 (20%)
By Designation: C-level (75%), D-level (15%), and Others (10%)
By Region: North America (70%), Europe (20%), APAC (7%), and the RoW (3%)
Key Players in the Digital Therapeutics Market
The prominent players in this market are Noom, Inc (US), Teladoc Health, Inc. (US), Omada Health, Inc. (US), WellDoc, Inc (US), Biofourmis (US), Better Therapeutics, Inc. (US), Amalgm Rx (US), CogniFit Inc (US), Headspace Health (US), Propeller Health (US), Virta Health Corp (US), 2Morrow, Inc. (US), Realizedcare (US), Canary Health (US), Twill Inc. (US), Click Therapeutics, Inc. (US), Akili, Inc. (US), Cognoa, Inc (US), Wellthy Therapeutics Pvt. Ltd. (India), Kaia Health (Germany), Ayogo (Canada), Mindable Health GmbH (Germany), Hinge Health, Inc. (US), and Freespira (US).
Research Coverage:
This report includes qualitative and quantitative analysis of the digital therapeutics market. The key objectives of the report are to estimate the size and future growth potential of the market across different segments, which includes sales channel, revenue model, application, offering and region. The report also comprises of extensive competitive analysis of the prominent market players, along with their financial information, recent developments, company profiles, recent developments, and prevalent market strategies.
Key Benefits of Buying the Report:
The report aims to assist market leaders and new entrants by offering close approximations of revenue figures for both the overall digital therapeutics market and its subsegments. Stakeholders can leverage this report to comprehend the competitive landscape, acquire insights for strategic business positioning, and formulate effective go-to-market strategies. Additionally, it provides stakeholders with the means to assess the market dynamics and furnishes information on crucial market opportunities, restraints, drivers, and challenges.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
Analysis of key drivers (increasing incidence of preventable chronic disease, rising focus on preventative healthcare, need to control healthcare costs, significant increase in venture capital investments), opportunities (growth prospects in emerging markets, large undiagnosed and untreated patient population, unexpected therapeutic applications) are influencing the growth of the digital therapeutics market.
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the digital therapeutics market.
Market Development: Comprehensive information detailing lucrative market - the report analyses the digital therapeutics market across various regions as well as countries.
Market Diversification: Exhaustive information about new software and programs, untapped geographies, recent developments, and investments in the digital therapeutics market.
Competitive Assessment: The report provides detailed insights on key players as well as key SME/upcoming players in the market. In-depth assessment of growth strategies, market shares, product and service offerings of players and key trends in the market is provided in the report. The report will enable stakeholders to understand the pulse of the digital therapeutics market and provide them with information such as drivers, challenges, restraints and opportunities.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS AND EXCLUSIONS
1.4 MARKET SCOPE
1.4.1 MARKETS COVERED
1.4.2 YEARS CONSIDERED
1.4.3 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 RESEARCH LIMITATIONS
1.7 SUMMARY OF CHANGES
1.8 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY TYPE OF BUYER AND REGION
FIGURE 37 TELADOC HEALTH, INC.: COMPANY SNAPSHOT (2022)
12.1.3 OMADA HEALTH, INC.
TABLE 273 OMADA HEALTH, INC.: BUSINESS OVERVIEW
12.1.4 WELLDOC, INC.
TABLE 274 WELLDOC, INC.: BUSINESS OVERVIEW
12.1.5 COGNIFIT, INC.
TABLE 275 COGNIFIT, INC.: BUSINESS OVERVIEW
12.1.6 HEADSPACE HEALTH
TABLE 276 HEADSPACE HEALTH: BUSINESS OVERVIEW
12.1.7 PROPELLER HEALTH
TABLE 277 PROPELLER HEALTH: BUSINESS OVERVIEW
12.1.8 2MORROW, INC.
TABLE 278 2MORROW, INC.: BUSINESS OVERVIEW
12.1.9 CANARY HEALTH
TABLE 279 CANARY HEALTH: BUSINESS OVERVIEW
12.1.10 CLICK THERAPEUTICS, INC.
TABLE 280 CLICK THERAPEUTICS: BUSINESS OVERVIEW
12.1.11 AKILI, INC.
TABLE 281 AKILI, INC.: BUSINESS OVERVIEW
12.1.12 WELLTHY THERAPEUTICS PVT. LTD.
TABLE 282 WELLTHY THERAPEUTICS PVT. LTD.: BUSINESS OVERVIEW
12.1.13 COGNOA, INC.
TABLE 283 COGNOA, INC.: BUSINESS OVERVIEW
12.1.14 TWILL INC.
TABLE 284 TWILL INC.: BUSINESS OVERVIEW
12.1.15 KAIA HEALTH SOFTWARE GMBH
TABLE 285 KAIA HEALTH SOFTWARE GMBH: BUSINESS OVERVIEW
12.1.16 BETTER THERAPEUTICS, INC.
TABLE 286 BETTER THERAPEUTICS, INC.: BUSINESS OVERVIEW
12.1.17 REALIZEDCARE
TABLE 287 REALIZEDCARE: BUSINESS OVERVIEW
12.1.18 BIOFOURMIS
TABLE 288 BIOFOURMIS: BUSINESS OVERVIEW
12.1.19 AYOGO INCORPORATED
TABLE 289 AYOGO INCORPORATED: BUSINESS OVERVIEW
12.1.20 AMALGAM RX, INC.
TABLE 290 AMALGAM RX, INC.: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 MINDABLE HEALTH GMBH
12.2.2 VIRTA HEALTH CORP.
12.2.3 HINGE HEALTH
12.2.4 OREXO AB
12.2.5 FREESPIRA, INC.
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)** might not be captured in case of unlisted companies.
